ALK and non-small cell lung carcinoma: However, we should acknowledge that EGFR testing (alongside testing for ALK fusion, ROS1 fusion, BRAF mutation, MET exon 14 skipping, and PD‐L1 expression) is recommended for patients with advanced or recurrent nonsquamous NSCLC in Japan.2